Evidence map›Paper›PMID 37767021›Full record

ArticleF1000Research2023

Toblerone: detecting exon deletion events in cancer using RNA-seq.

Andrew Lonsdale, Andreas Halman, Lauren Brown, Hansen Kosasih, Paul Ekert, Alicia Oshlack

Abstract read
In one paragraph

Article in F1000Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Biomedicines · 2024
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrew LonsdaleSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.ORCID 0000-0002-0292-2880
Andreas HalmanSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.
Lauren BrownMurdoch Children's Research Institute, Parkville, VIC, 3052, Australia.
Hansen KosasihMurdoch Children's Research Institute, Parkville, VIC, 3052, Australia.ORCID 0000-0002-0428-6195
Paul EkertSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.
Alicia OshlackSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.ORCID 0000-0001-9788-5690

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is driven by mutations of the genome that can result in the activation of oncogenes or repression of tumour suppressor genes. In acute lymphoblastic leukemia (ALL) focal deletions in IKAROS family zinc finger 1 (IKZF1) result in the loss of zinc-finger DNA-binding domains and a dominant negative isoform that is associated with higher rates of relapse and  poorer patient outcomes. Clinically, the presence of IKZF1 deletions informs prognosis and treatment options. In this work we developed a method for detecting exon deletions in genes using RNA-seq with application to IKZF1. We developed a pipeline that first uses a custom transcriptome reference consisting of transcripts with exon deletions.  Next, RNA-seq reads are mapped using a pseudoalignment algorithm to identify reads that uniquely support deletions. These are then evaluated for evidence of the deletion with respect to gene expression and other samples. We applied the algorithm, named Toblerone, to a cohort of 99 B-ALL paediatric samples including validated IKZF1 deletions. Furthermore, we developed a graphical desktop app for non-bioinformatics users that can quickly and easily identify and report deletions in IKZF1 from RNA-seq data with informative graphical outputs.

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaChildExonsHumansMutationPrognosisRNA-SeqcancerRNA-seq

Identifiers

PMID37767021
PMCPMC10521068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.